Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report)'s stock had its "hold" rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports.
Separately, HC Wainwright reissued a "neutral" rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, April 8th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Verrica Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $9.50.
Get Our Latest Analysis on VRCA
Verrica Pharmaceuticals Price Performance
Shares of VRCA traded up $0.04 during mid-day trading on Wednesday, hitting $0.52. The company's stock had a trading volume of 249,091 shares, compared to its average volume of 578,273. The stock has a market capitalization of $48.18 million, a price-to-earnings ratio of -0.29 and a beta of 1.68. Verrica Pharmaceuticals has a fifty-two week low of $0.38 and a fifty-two week high of $11.41. The firm has a 50-day moving average price of $0.60 and a 200 day moving average price of $0.86.
Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last announced its earnings results on Tuesday, March 11th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The company had revenue of $0.34 million during the quarter, compared to analysts' expectations of $1.30 million. As a group, equities analysts anticipate that Verrica Pharmaceuticals will post -1.46 EPS for the current fiscal year.
Institutional Trading of Verrica Pharmaceuticals
A number of large investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its position in Verrica Pharmaceuticals by 347.5% in the 4th quarter. Bank of America Corp DE now owns 143,818 shares of the company's stock valued at $101,000 after acquiring an additional 111,678 shares in the last quarter. Caligan Partners LP acquired a new stake in Verrica Pharmaceuticals during the 4th quarter worth $5,201,000. Boothbay Fund Management LLC bought a new position in shares of Verrica Pharmaceuticals during the 4th quarter valued at about $1,811,000. Heights Capital Management Inc. bought a new position in Verrica Pharmaceuticals in the fourth quarter valued at approximately $246,000. Finally, Renaissance Technologies LLC lifted its position in Verrica Pharmaceuticals by 57.7% in the 4th quarter. Renaissance Technologies LLC now owns 233,300 shares of the company's stock valued at $163,000 after acquiring an additional 85,336 shares in the last quarter. 42.45% of the stock is currently owned by institutional investors.
About Verrica Pharmaceuticals
(
Get Free Report)
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
Featured Stories
Before you consider Verrica Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verrica Pharmaceuticals wasn't on the list.
While Verrica Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
